As GSK jettisons consumer brands, smaller marketer sees boon

Share this article:
As GSK jettisons consumer brands, smaller marketer sees boon
As GSK jettisons consumer brands, smaller marketer sees boon

GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.

The 17 OTC brands, which do not include weight-loss product Alli, were sold for £426 million ($660 million) in cash to US-based Prestige. The products spanned primarily the adult analgesic (BC, Goody's, Ecotrin), gastrointestinal (Beano, Gaviscon, Tagamet), ear-wax relief (Debrox) and sleep-aid (Sominex) categories.

It was a bittersweet sale for GSK. Prestige's purchase price for the North American brands amounted to more than three times sales, but cash was reduced by taxes and transaction costs. GSK will receive net cash proceeds of only £242 million ($375 million), observed JP Morgan analyst Alexandra Hauber in an investor note.

Moreover, the drugmaker would have preferred to unload a much bigger consumer portfolio to one buyer. Other largely European-based brands with another $600 million in sales, including Alli, await a buyer.

GSK is looking to focus on consumer brands in oral health, wellness/OTC and nutrition like Sensodyne, Panadol and Horlicks, while jettisoning others. The firm, which announced its intention to divest the non-core consumer assets in late 2010, has not disclosed the total number of brands on the block.

For Prestige, a US marketer of over-the-counter drug and household cleaning products, the buy complements a healthcare lineup whose major brands include Chloraseptic, Clear Eyes and Compound W.

The GSK acquisition, coming on the heels of recent acquisitions of five brands from Blacksmith Brands and Dramamine from Johnson & Johnson over the past year, gave the smaller marketer platforms to compete in two new categories—adult aspirin-based analgesics and gastrointestinal—while also adding scale.

“Following the completion of the [GSK] transaction, Prestige's top 10 brands will average sales of $35 million (compared with $20 million a year ago),” William Blair analyst Jon Andersen told investors.

That heft may enable the company to better support investment in innovation and marketing. “At a minimum,” Andersen added, “we expect Prestige to line-extend the brands and provide additional marketing support, both of which could breathe additional life into the acquired products.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...